Wooseok SEO
Kyoto University Graduate School of Medicine
Kyoto University Graduate School of Medicine
Center for Cancer Immunotherapy and Immunobiology (CCII)
Division of Cancer Immune Multicellular System Regulation
Division of Cancer Immune Multicellular System Regulation
Recent research highlight
SATB1 preserves CD4⁺ T cell fidelity and establishes Treg function in anti-tumor immunity
Wooseok Seo, Chengcheng Zou, Krutula Nair, Haruhiko Koseki, Terumi Kohwi-Shigematsu, Hiroyoshi Nishikawa, Ichiro Taniuchi
Life Science Alliance 2026年9月
The Fate of T Cells and Anti-Tumor Immunity Governed by the Genome Organizer SATB1
"How is the identity of immune cells maintained?" This fundamental question initiated our research. We elucidated how SATB1, a known genome organizer, is involved in regulatory T cell (Treg) function.
The key to this study was utilizing a Thpok-cre mouse model to specifically delete SATB1 only in "mature T cells after CD4 lineage commitment," thereby excluding the effects of SATB1 deletion during early T cell differentiation seen in conventional CD4-Cre models. By focusing on this critical window—after CD4 lineage commitment but before FoxP3 expression—we successfully uncovered the true role of SATB1, which had been overlooked in traditional CD4-Cre or Foxp3-Cre models.
What emerged was the remarkable duality of SATB1. In conventional CD4+ T cells, SATB1 strongly represses Foxp3 expression, acting as a brake against aberrant FoxP3 expression to protect lineage fidelity. However, in Tregs, it switches to become a FoxP3 cofactor, working to build an immunosuppressive barrier. Consequently, we demonstrated that deleting SATB1 disrupts this Treg-mediated immunosuppressive barrier, unleashing the function of CD8+ T cells (killer T cells) and dramatically enhancing anti-tumor immunity.
SATB1 enforces CD4+ effector T cell lineage stability by repressing Foxp3 via DNA methylation
Wooseok Seo, Chengcheng Zou, Krutula Nair, Haruhiko Koseki, Terumi Kohwi-Shigematsu, Hiroyoshi Nishikawa, Ichiro Taniuchi
Biochemical and Biophysical Research Communications 827 154026-154026 2026年8月
An Epigenetic "Key" Preventing Aberrant Gene Expression: Maintenance of T Cell Identity by SATB1
What happens if conventional CD4+ T cells (helper T cells) mistakenly turn on Foxp3, the master gene for Tregs? This study investigates the epigenetic regulatory mechanisms by which the genome organizer SATB1 prevents such aberrant gene expression. While it was previously known that SATB1 regulates Foxp3 expression, the detailed epigenetic molecular mechanisms remained unclear.
Here, using the Thpok-cre system, we generated a mouse model in which SATB1 is specifically deleted only in mature T cells post-CD4 lineage commitment. Remarkably, even in the absence of conventional differentiation-inducing signals (TGF-β), Foxp3 spontaneously began to express, leading to the sudden appearance of an atypical "CD25- FoxP3+" population. Furthermore, genetic analysis revealed that this "aberrant expression" of FoxP3 caused by SATB1 deficiency is mediated by the DNA demethylases TET2 and TET3.
Therefore, SATB1 firmly protects the identity (fidelity) of CD4+ T cells by controlling TET enzyme activity to properly maintain DNA methylation, thereby preventing the erroneous expression of Foxp3.
Genetic Disruption of Pdcd-1 Upstream Enhancer Boosts T Cell Function and Antitumor Responses
Chandsultana Jerin, Wooseok Seo, Hiroyoshi Nishikawa
Immunology Letters 107171-107171 2026年3月
Regulating PD-1 Expression: Enhancer Manipulation Focusing on Heterogeneity and Anti-Tumor Immunity
PD-1 plays a central role in cancer immunotherapy. In reality, its expression levels vary depending on the cell type and state, yet the significance of this heterogeneity has not been sufficiently considered.
Therefore, we focused on a specific enhancer (-23k enhancer) that drives PD-1 expression when T cells fall into an exhausted state, and generated a mouse model lacking this enhancer. Analysis within the tumor microenvironment showed a remarkable and successful reduction of PD-1 expression not only in "exhausted CD8+ T cells" but also across conventional CD4+ T cells, Tregs, and even γδ T cells.
By fundamentally weakening PD-1 expression in exhausted immune cells, the "exhausted state" of CD8+ T cells was vastly improved, resulting in the induction of potent anti-tumor immunity. This achievement strongly indicates that controlling PD-1 expression via "enhancer manipulation"—an approach distinct from existing antibody drugs targeting proteins—could serve as a highly promising therapeutic target for next-generation cancer immunotherapies.
Research History
Laboratory for Transcriptional Regulation in Immunity, RIKEN Center for Integrative Medical Sciences (2009.11 – 2019.10)
I engaged in elucidating the "fundamental principles of gene expression regulation"—how genomic information, the blueprint of life, is read to construct precise biological systems. Under the leadership of Team Leader Ichiro Taniuchi, I focused on the functional analysis of transcription factor complexes and the dynamics of higher-order chromatin structures, revealing the processes of T cell differentiation and activation at the molecular level. During this period, in addition to mastering genetically modified mouse generation and wet-lab molecular biology techniques, I acquired dry-lab skills in epigenomic and bioinformatic analyses, such as ChIP-seq and ATAC-seq. The ability to seamlessly execute research—formulating hypotheses, generating mouse models for validation, and deriving answers through cutting-edge genomic analysis—remains the core of my current research style.
Department of Molecular and Cellular Immunology, Graduate School of Medicine, Nagoya University (2019.11 – 2025.3)
Building on the biochemical and molecular biological techniques cultivated at RIKEN, I expanded my research scope to the "breakdown of molecular mechanisms in disease." In Professor Hiroyoshi Nishikawa's laboratory, I analyzed the mechanisms of cellular dysfunction (exhaustion) in the tumor microenvironment from the perspectives of metabolism, signal transduction, and transcriptional regulation. Furthermore, based on the unique concept of "neuro-immune crosstalk" conceived during my research, I established an Interdisciplinary Research Unit with support from the MEXT Program for Promoting the Enhancement of Research Universities, serving as the Unit Leader. In this unit, we merged classical biochemical methods with cutting-edge genetic engineering, driving the creation of new academic fields through interdisciplinary fusion.
Principal Investigator (FOREST Program, JST - Shiomi Panel) (2023.4 – Present)
https://www.jst.go.jp/souhatsu/research/panel_shiomi.html
Within the JST FOREST (Fusion Oriented REsearch for disruptive Science and Technology) Program, I am working on "Elucidating the molecular identity and function of transcription factories through locus-specific analysis." The goal is to uncover the molecular basis of the "transcription factory" hypothesis, where multiple genes gather in specific nuclear regions to undergo efficient transcriptional regulation. The core of this research lies in utilizing Locus-specific ChIP to directly capture transcription complexes formed at specific genomic regions. Through this, we aim to quantitatively analyze the 4D dynamics of specific loci (local environments), which cannot be observed using the "averaged data" of conventional ChIP-seq. Unraveling the transcription factories of the immune system holds the potential to enable the identification and evaluation of novel immune checkpoint molecules, thereby accelerating applications in cancer immunology research.
Division of Cancer Immunology and Multicellular System Control, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University (2025.4 – Present)
Since the 2025 academic year, I have continued my research under Professor Hiroyoshi Nishikawa as an Associate Professor in the Division of Cancer Immunology and Multicellular System Control at the Kyoto University Center for Cancer Immunotherapy and Immunobiology (CCII), founded by Dr. Tasuku Honjo. Here, I am taking on a new approach that views cancer immunity not merely as single-cell analysis but as a "multicellular system" at the organismal level. My strength is a comprehensive, end-to-end analytical style: taking insights gained from omics analysis of clinical specimens, reproducing them in precise, custom-made disease mouse models, and demonstrating their in vivo function. Currently, I am particularly focused on establishing "Chrono-immunology"—understanding cancer immunity through the "time axis," such as circadian rhythms and aging, rather than just at the molecular level. Through these studies, I aim to promote translational research (TR) that scientifically resolves clinical questions, contributing to the creation of a world where we can not only treat cancer but ultimately prevent it in the future.
Research Methods
Generation of genetically modified mice (ES cells, CRISPR/Cas9)
Molecular biological analysis (Western Blotting, ELISA)
Cellular biological analysis (Flow cytometry, RNA-seq, scRNA-seq)
Epigenetic analysis (ChIP-seq, ATAC-seq, Hi-C)
Bioinformatics (NGS data analysis)
ABOUT US
D4: ZHAO Quiyu
D4: CHEN Hao
D2: LIU Yuhan
D1: Shunsuke OKUYAMA